Lectures and seminars CBB seminar: Dynamic clinical trial with Markus Mayrhofer

ProBio - Prostate Biomarkers

ProBio is an international, multi-centre, outcome-adaptive, multi-arm, multiple assignment, randomised controlled, biomarker-driven, platform trial in men with de novo metastatic hormone-sensitive (mHSPC) or metastatic castration-resistant (mCRPC) prostate cancer. Patients are randomised to receive either standard-of-care or one of the experimental treatment arms with a novel hormonal agent (NHA), taxane- or platinum-based chemotherapy, or PARP inhibitor, based on biomarker signatures inferred from sequencing of cell-free DNA (cfDNA) and a prostate-specific gene panel.

Before the seminar, a limited number of sandwiches and drinks will be served on a “First come – first served” basis starting 12:00. Show up early and network!

The seminar is held in English.